Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MANNITOL 5% IN PLASTIC CONTAINER vs MANNITOL 15% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Mannitol is an osmotic diuretic that increases the osmolarity of the glomerular filtrate, reducing tubular reabsorption of water and solutes. It also draws water from intracellular spaces into the extracellular fluid, reducing cerebral edema and intraocular pressure.
Mannitol is an osmotic diuretic that increases plasma osmolality, thereby drawing water from extravascular spaces into the plasma and reducing intracranial pressure. It also increases renal tubular osmotic pressure, inhibiting water reabsorption and promoting diuresis.
Reduction of intracranial pressure and cerebral edema,Reduction of elevated intraocular pressure,Promotion of diuresis in acute renal failure (e.g., oliguric phase),Facilitation of urinary excretion of toxic substances (e.g., salicylates, barbiturates)
Reduction of elevated intracranial pressure (FDA-approved),Promotion of diuresis in acute renal failure (FDA-approved),Reduction of intraocular pressure (FDA-approved),Irrigant in transurethral prostatic resection (FDA-approved),Enhancement of urinary excretion of toxic substances (off-label)
50-100 g intravenously over 30-60 minutes for initial dose in acute renal failure or cerebral edema; maintenance dose 25-50 g every 6-8 hours based on serum osmolality and urine output.
Intravenous: 50-100 g (1-2 g/kg) as a 15-25% solution over 30-60 minutes. For cerebral edema: 0.25-1 g/kg IV every 4-6 hours. For oliguric acute kidney injury: test dose of 0.2 g/kg IV over 3-5 minutes; if urine output >50 m L/hr, administer 50-100 g as 15-20% solution over 2-6 hours.
Terminal elimination half-life: 1–2 hours (adults with normal renal function); prolonged to 24–48 hours in severe renal impairment.
Terminal elimination half-life approximately 0.5–1 hour in normal renal function; prolonged to 24–36 hours in anuria or severe renal impairment.
Mannitol is not metabolized; it is excreted unchanged by the kidneys via glomerular filtration, with minimal tubular reabsorption.
Mannitol is not metabolized; it is excreted unchanged by the kidneys via glomerular filtration, with a small amount reabsorbed in the proximal tubule.
Renal: >90% as unchanged drug via glomerular filtration; negligible biliary or fecal elimination.
Renal: >90% excreted unchanged in urine within 24 hours; minimal biliary/fecal elimination (<2%).
Negligible (<0.5%); no specific binding proteins.
Negligible protein binding (<0.5%); no specific binding proteins identified.
0.5–0.6 L/kg; distributes primarily in extracellular fluid, does not cross cell membranes except under specific conditions (e.g., disrupted blood-brain barrier).
Approximately 0.5–0.7 L/kg (confined to extracellular fluid space; does not cross cell membranes significantly).
IV: 100%. Oral: negligible (<10%) due to poor absorption; not administered orally for systemic effects.
Intravenous: 100% (only route used clinically); no oral bioavailability due to poor absorption and osmotic diarrhea.
Avoid use in anuria; GFR < 20 m L/min: contraindicated; GFR 20-50 m L/min: use with caution, monitor serum osmolality and fluid balance, reduce dose by 50% and extend interval to every 12-24 hours.
Contraindicated in anuria. GFR <15 m L/min: avoid use. GFR 15-30 m L/min: use with caution, monitor serum osmolarity and electrolytes. No specific dose adjustment for mild-moderate renal impairment; clinical judgment required.
No specific dose adjustment for hepatic impairment; caution in ascites due to potential volume overload.
No specific dose adjustment for hepatic impairment; monitor for fluid and electrolyte disturbances.
0.25-2 g/kg intravenously over 30-60 minutes, not to exceed 60 g in total dose; dose based on clinical indication and serum osmolality.
Intravenous: 1-2 g/kg as a 15-20% solution over 30-60 minutes. For acute renal failure: test dose of 0.2 g/kg IV over 30 minutes; if urine output >1 m L/kg/hr, continue with 0.5-1 g/kg every 4-6 hours. For cerebral edema: 0.25-1 g/kg IV every 4-6 hours. Maximum infusion rate: 60 g/hour.
Start at lower end of dosing range (25-50 g), monitor renal function and serum osmolality; increased risk of volume overload and electrolyte disturbances; avoid if pre-existing renal impairment.
Start at lower end of dosing range; monitor renal function, fluid balance, and electrolytes closely due to age-related decreased renal function and higher risk of volume overload.
None.
None.
Monitor renal function, serum electrolytes, fluid balance, and osmolality during therapy.,Risk of volume overload, pulmonary edema, or heart failure in patients with impaired cardiac function.,May cause electrolyte disturbances (e.g., hyponatremia, hyperkalemia) and dehydration.,Use with caution in patients with severe renal impairment, anuria, or congestive heart failure.,Hypersensitivity reactions may occur.
Use with caution in patients with heart failure, pulmonary congestion, or renal impairment due to risk of fluid overload and electrolyte disturbances.,Monitor serum electrolytes, osmolality, and renal function during therapy.,Avoid in patients with anuria due to severe renal disease.,Rapid infusion may cause circulatory overload resulting in hyponatremia and hyperosmolality.
Anuria due to severe renal disease,Severe pulmonary congestion or edema,Active intracranial bleeding (except during craniotomy),Severe dehydration,Hypersensitivity to mannitol
Anuria due to severe renal disease,Severe pulmonary congestion or edema,Active intracranial bleeding (except during craniotomy),Dehydration,Hypersensitivity to mannitol
No specific food interactions. Maintain adequate fluid intake unless fluid restriction is prescribed (e.g., for hyponatremia or cerebral edema). Avoid excessive salt to prevent fluid retention.
No specific food interactions. Maintain adequate hydration unless contraindicated. Avoid excessive salt intake as it may counteract diuretic effect.
Mannitol is a pregnancy category C drug. In the first trimester, use is generally avoided due to lack of safety data; however, no teratogenic effects have been reported in animal studies at clinically relevant doses. In the second and third trimesters, administration may cause fetal dehydration, electrolyte imbalances, or osmotic shifts, particularly with high doses or prolonged infusion. Use only if clearly indicated (e.g., for cerebral edema in preeclampsia/eclampsia). Fetal monitoring for signs of fluid and electrolyte disturbance is recommended.
Mannitol is a pregnancy category C drug. There are no adequate and well-controlled studies in pregnant women. Animal studies have not been conducted. Mannitol should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. In the first trimester, risks are unknown; in second and third trimesters, maternal administration may cause fetal electrolyte disturbances due to osmotic diuresis.
It is unknown if mannitol is excreted in human breast milk. Due to its low oral bioavailability (approximately 20%), infant exposure via breastfeeding is expected to be minimal. However, caution is advised, especially in neonates with renal impairment. No M/P ratio is available. Consider the benefits of breastfeeding against the potential for infant effects.
It is not known whether mannitol is excreted in human milk. The M/P ratio is not established. Caution should be exercised when mannitol is administered to a nursing woman. The drug should be used only if clearly needed, considering the potential for adverse effects in nursing infants such as osmotic diuresis and electrolyte imbalance.
Pregnancy does not significantly alter mannitol pharmacokinetics. However, due to increased plasma volume and glomerular filtration rate during pregnancy, careful monitoring of therapeutic response and adverse effects is warranted. Dose adjustments are not routinely required but should be individualized based on maternal weight (obesity or edema), renal function, and clinical indication. Use the lowest effective dose with close monitoring of output and electrolytes.
Pregnancy may alter pharmacokinetics of mannitol due to increased plasma volume and renal blood flow, potentially increasing clearance. However, specific dose adjustments are not recommended. The usual adult dose (50-200 g per 24 hours) may be used with careful monitoring of maternal hydration status, urine output, and serum osmolality to avoid volume depletion or overload. No standard dose reduction is indicated.
Mannitol 5% is an osmotic diuretic. Monitor serum electrolytes, osmolality, and renal function before and during infusion. Avoid extravasation due to risk of tissue damage. Use in patients with intracranial hypertension requires careful titration to maintain cerebral perfusion pressure. Contraindicated in anuria, pulmonary edema, or active intracranial bleeding.
Mannitol 15% is an osmotic diuretic used primarily for reduction of intracranial pressure (ICP) and cerebral edema. In emergency settings, administer via IV bolus (0.25-1 g/kg) over 30-60 minutes; onset of ICP reduction occurs within 15-30 minutes. Monitor serum osmolality and avoid if >320 m Osm/L. Use with caution in acute tubular necrosis. Can cause transient volume expansion followed by diuresis; watch for pulmonary edema in heart failure patients. Crystallization may occur at low temperatures; warm and inspect before use.
This medication increases urine output; stay hydrated unless advised otherwise.,Report difficulty urinating, chest pain, or shortness of breath immediately.,Avoid sudden position changes to prevent dizziness from fluid shifts.,Inform your doctor if you have kidney disease, heart failure, or are pregnant.
This medication is given intravenously to reduce swelling in the brain.,You may experience increased urination, headache, or dry mouth.,Report any chest pain, difficulty breathing, or unusual swelling.,Do not stop or change the infusion rate without medical advice.,Tell your doctor if you have kidney disease, heart failure, or electrolyte imbalances.
"Concomitant use of clonidine and mannitol may potentiate the hypotensive effect of clonidine, leading to an increased risk of severe hypotension, syncope, and orthostatic hypotension. Mannitol, an osmotic diuretic, can cause volume depletion and electrolyte disturbances, which may exacerbate clonidine's sympatholytic effects on blood pressure regulation. This interaction is particularly concerning in patients with pre-existing cardiovascular conditions or those receiving other antihypertensive agents."
"Mannitol, an osmotic diuretic, induces intravascular volume expansion followed by diuresis, which can cause electrolyte disturbances, particularly hypokalemia and hypomagnesemia. Nifedipine, a calcium channel blocker, can further lower blood pressure through vasodilation. The combination may enhance the hypotensive effect and increase the risk of arrhythmias due to electrolyte imbalances."
"Coadministration of candesartan cilexetil, an angiotensin II receptor blocker (ARB), with mannitol, an osmotic diuretic, can result in an additive hypotensive effect due to overlapping mechanisms that reduce blood pressure. Mannitol increases renal water excretion, decreasing plasma volume and preload, while candesartan inhibits angiotensin II-mediated vasoconstriction and aldosterone secretion, leading to vasodilation and reduced afterload. This combined effect may predispose patients to symptomatic hypotension, especially in those with volume depletion or renal impairment."
"Concomitant use of clonidine and mannitol may potentiate the hypotensive effect of clonidine, leading to an increased risk of severe hypotension, syncope, and orthostatic hypotension. Mannitol, an osmotic diuretic, can cause volume depletion and electrolyte disturbances, which may exacerbate clonidine's sympatholytic effects on blood pressure regulation. This interaction is particularly concerning in patients with pre-existing cardiovascular conditions or those receiving other antihypertensive agents."
"Mannitol, an osmotic diuretic, induces intravascular volume expansion followed by diuresis, which can cause electrolyte disturbances, particularly hypokalemia and hypomagnesemia. Nifedipine, a calcium channel blocker, can further lower blood pressure through vasodilation. The combination may enhance the hypotensive effect and increase the risk of arrhythmias due to electrolyte imbalances."
"Coadministration of candesartan cilexetil, an angiotensin II receptor blocker (ARB), with mannitol, an osmotic diuretic, can result in an additive hypotensive effect due to overlapping mechanisms that reduce blood pressure. Mannitol increases renal water excretion, decreasing plasma volume and preload, while candesartan inhibits angiotensin II-mediated vasoconstriction and aldosterone secretion, leading to vasodilation and reduced afterload. This combined effect may predispose patients to symptomatic hypotension, especially in those with volume depletion or renal impairment."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MANNITOL 5% IN PLASTIC CONTAINER vs MANNITOL 15% IN PLASTIC CONTAINER, answered by our medical review team.
MANNITOL 5% IN PLASTIC CONTAINER is a Osmotic Diuretic that works by Mannitol is an osmotic diuretic that increases the osmolarity of the glomerular filtrate, reducing tubular reabsorption of water and solutes. It also draws water from intracellular spaces into the extracellular fluid, reducing cerebral edema and intraocular pressure.. MANNITOL 15% IN PLASTIC CONTAINER is a Osmotic Diuretic that works by Mannitol is an osmotic diuretic that increases plasma osmolality, thereby drawing water from extravascular spaces into the plasma and reducing intracranial pressure. It also increases renal tubular osmotic pressure, inhibiting water reabsorption and promoting diuresis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MANNITOL 5% IN PLASTIC CONTAINER and MANNITOL 15% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Osmotic Diuretic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MANNITOL 5% IN PLASTIC CONTAINER is: 50-100 g intravenously over 30-60 minutes for initial dose in acute renal failure or cerebral edema; maintenance dose 25-50 g every 6-8 hours based on serum osmolality and urine output.. The standard adult dose of MANNITOL 15% IN PLASTIC CONTAINER is: Intravenous: 50-100 g (1-2 g/kg) as a 15-25% solution over 30-60 minutes. For cerebral edema: 0.25-1 g/kg IV every 4-6 hours. For oliguric acute kidney injury: test dose of 0.2 g/kg IV over 3-5 minutes; if urine output >50 m L/hr, administer 50-100 g as 15-20% solution over 2-6 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining MANNITOL 5% IN PLASTIC CONTAINER and MANNITOL 15% IN PLASTIC CONTAINER. Mannitol, an osmotic diuretic, induces intravascular volume expansion followed by diuresis, which can cause electrolyte disturbances, particularly hypokalemia and hypomagnesemia. Nifedipine, a calcium channel blocker, can further lower blood pressure through vasodilation. The combination may enhance the hypotensive effect and increase the risk of arrhythmias due to electrolyte imbalances. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. MANNITOL 5% IN PLASTIC CONTAINER is classified as Category A/B. Mannitol is a pregnancy category C drug. In the first trimester, use is generally avoided due to lack of safety data; however, no teratogenic effects have been reported in animal s. MANNITOL 15% IN PLASTIC CONTAINER is classified as Category A/B. Mannitol is a pregnancy category C drug. There are no adequate and well-controlled studies in pregnant women. Animal studies have not been conducted. Mannitol should be used during. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.